A | B | C | D | E | F | G | H | I | J | K | L | M | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | a | SolvingMS.org Regenerative Trials Database Click Links for Enrollment Info | Proposed Modality | Country | MS Type For Trial | EBV Rx | Trial Phase | Phase Status | Years Until Approval | FDA Approval (est.) | Pipeline Also in Trial For | Phase Score Most Weight | Effective- ness | FDA Acceler- ation | Overall Score = Phase Score^2 xEffectiveness +Acceleration | Start date | 27 PPMS 15 SPMS 23 RRMS 12 ALL TYPES | https://www.facebook.com/groups/solvingms/ | http://bit.ly/SolvingMS_Database | ||||||||||||
2 | SolvingMS.org MS Research Database | Curative & Regenerative Clinical Trials | As of: | 2/11/2025 | Overall Score | ||||||||||||||||||||||||||
3 | Trial Finder | Enroll in Recruiting Trials! | Copyright © 2025 Solving MS - All Rights Reserved | Ph 3=10 | Ph 2=39 | Ph 1=19 | |||||||||||||||||||||||||
6 | PPMS 16 SPMS 15 RRMS 23 | ||||||||||||||||||||||||||||||
25 | Policy and Research Papers | ||||||||||||||||||||||||||||||
26 | Accelerate Regenerative Medicine Act (ARMA) by Solving MS | Whitepaper: Legislation to Address the National Emergency of Infection-Associated Chronic Conditions & Autoimmune Disease. | |||||||||||||||||||||||||||||
27 | Antivirals & Other Treatments for EBV in MS | History of research on EBV as the cause of MS and conclusive proof published Jan. 2022. Includes clinical trials of antivirals and other approaches for EBV. Also see Should I Get an EBV Test If I Have MS? | |||||||||||||||||||||||||||||
28 | Paxlovid: Epstein-Barr Virus Antiviral Effect? | Patient Reported Outcomes of Paxlovid benefits for: Long Covid, MS, ME/CFS and primary EBV. | |||||||||||||||||||||||||||||
29 | Gregory-MS AI Search Engine for all MS papers and clinical trials | Start with the Observatory to see all MS therapy research over time. | |||||||||||||||||||||||||||||
30 | Collaborate with SolvingMS! | Join our Research Study Group! 1.6k members tracking the research! All disease types welcome. See Pipeline column. We can win this battle faster together. | |||||||||||||||||||||||||||||
31 | MS Clinical Trials | ||||||||||||||||||||||||||||||
32 | 1 | Sanofi, BTKi Tolebrutinib | Remyelination Slow-disability EBV-Antiviral | Many | nrSP | Treat | 3 | Recruiting | 1 | 2026 | MS | 3 | 2.5 | Break- through Therapy | 3 | 26 | |||||||||||||||
33 | 2 | Immunic, IMU-838 Vidofludimus_Calcium | ↓ Microglial Astrocyte Neuroprotective Anti-inflammatory EBV-Antiviral | Many | RR ENSURE-1 ENSURE-2 | Treat | 3 | Recruiting | 1 | 2026 | MS UC CD | 3 | 2.75 | 25 | |||||||||||||||||
34 | 3 | Sanofi, Frexalimab Trial Info | Remyelination Immune-tolerance Slow-disability | USA QUEBEC | SP | Treat | 3 | Recruiting | 2 | 2027 | MS | 3 | 2.75 | 25 | |||||||||||||||||
35 | 4 | Sanofi, Frexalimab Trial Info | Remyelination Immune-tolerance Slow-disability | USA QUEBEC | RR | Treat | 3 | Recruiting | 2 | 2027 | MS | 3 | 2.75 | 25 | 2023-12-27 | 2026-12-23 | 2028-03-24 | ||||||||||||||
36 | 5 | BTKi Fenebrutinib | Remyelination Slow-disability EBV-Antiviral | Many | RR PP | Treat | 3 | Active, Not Recruiting | 1.5 | 2026.5 | MS | 3 | 2.5 | 23 | 2023-12-13 | 2027-05-06 | 2027-05-06 | ||||||||||||||
37 | 6 | FIRMS EBV - Spironolactone vs Tenofovir Alafenamide Info Trial | EBV Antiviral | Austrailia | RR | Treat | 3 | Not yet recruiting Planned 2025 | 3 | 2028 | MS | 3 | 2.5 | 23 | |||||||||||||||||
38 | 7 | Griffith University, Spironolactone & Famciclovir for EBV Info STOP-MS Trial | EBV Antiviral | Australia All States | SP PP | Treat | 3 | Not yet recruiting Planned 2025 | 3 | 2028 | MS | 3 | 2.5 | 23 | |||||||||||||||||
39 | 8 | Novartis, BTKi Remibrutinib Trials | Remyelination Slow-disability | Many | RR | Treat | 3 | Recruiting | 2 | 2027 | MS | 3 | 2.5 | 23 | |||||||||||||||||
41 | 10 | Clemastine for Remyelinating Internuclear Ophthalmoparesis in MS | Remyelination | Amsterdam | ALL | 3 | Recruiting or Off-label precription | 2 | 2027 | MS | 3 | 2 | 18 | 80 | 2022-08-30 | 2024-05 | 2026-11 | ||||||||||||||
42 | 11 | Octopus MS: Metformin, Clemastine, Alpha Lipoic Acid Trial | Remyelination | UK | SP PP | 3 | Recruiting or Off-label precription | 3 | 2028 | MS | 3 | 2 | 18 | ||||||||||||||||||
43 | 12 | Nervgen, NVG-291 | Axonal regeneration Neurogenesis Remyelination Neuroplasticity | USA | RR | 2 | SCI Q2 2025 | 5.5 | 2030.5 | SCI MS AD ALS STROKE | 2 | 3 | Priority Review | 3 | 15 | ||||||||||||||||
44 | 13 | Immunic, IMU-838 Vidofludimus_Calcium | Anti-inflammatory immunomodulator Neuroprotective Antiviral | Many | SP PP CALLIPER | Treat | 2 | Recruiting | 4 | 2029 | MS UC | 2.75 | 2.75 | 21 | |||||||||||||||||
45 | 14 | Clene, CNM-Au8 Nanogold | Remyelination Neuroregenerative Mitochondria repair | USA | RR | 2 | Completed | 3 | 2028 | MS ALS PD | 2.75 | 2.75 | 21 | ||||||||||||||||||
46 | 15 | Tisch MS Center, Stem Cells | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | USA | SP PP | 2 | Completed Published | 3 | 2028 | MS | 2.75 | 2.5 | Priority Review | 3 | 22 | ||||||||||||||||
47 | 16 | Hope Biosciences, Stem Cells | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | USA | RR | 2 | Completed 2024 Publication Pending | 3 | 2028 | MS C19 LCoviD SCI PD... | 2.75 | 2.5 | 19 | ||||||||||||||||||
48 | 17 | Brainstorm, NurOwn Stem Cells | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | USA | SP PP | 2 | Completed Published | 3 | 2028 | MS ALS | 2.75 | 2.5 | 19 | 2023-06-01 | |||||||||||||||||
49 | 18 | Hadassah, Stem Cells Video Info Trial | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | Israel | SP PP | 2 | Ph 2 Published Ph 3 Planned | 3 | 2028 | MS | 2.75 | 2.5 | 19 | ||||||||||||||||||
50 | 19 | Clene, CNM-Au8 Nanogold | Remyelination Neuroregenerative Mitochondria repair | USA | SP PP | 2 | Active, Not Recruiting | 4 | 2029 | MS ALS PD | 2.5 | 2.75 | 17 | ||||||||||||||||||
51 | 20 | Imcyse, Imotopes Info Trial | MBP-tolerizing | Moldova | RR | Treat | 1/2 | Active, Not Recruiting | 4 | 2029 | MS | 2 | 4 | 16 | 150 | 2022-04-12 | 2025-05-23 | 2025-12-31 | |||||||||||||
52 | 21 | Tiziana, Foralumab Info Trial | ↓ Microglial Activity T-cell balance Neuroprotective Anti-inflammatory | USA | SP | 2 | Recruiting | 3 | 2028 | MS AD ALS Crohn's C-19 | 2 | 2.75 | Fast Track | 2 | 13 | 54 | 2023-11-15 | 2024-11 | 2024-11 | ||||||||||||
53 | 22 | Diaprotectome (DITPA) | Remyelination Neuroregenerative Mitochondria repair | Greece Australia | SP PP | 2 | Planned 2025 | 5.5 | 2030.5 | MS | 2 | 2.75 | 11 | 400 | 2025 | ||||||||||||||||
54 | 22 | SMART-MS Stem Cells | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | Norway | SP PP | 2 | Active, Not Recruiting | 3.5 | 2028.5 | MS | 2 | 2.5 | 10 | 18 | 2021 | ||||||||||||||||
55 | 24 | The TAF-MS study: Tenofovir alafenamide fumarate (TAF) for EBV in MS – a proof of concept study | EBV Antiviral | Norway | RR | Treat | Pilot | Announced 2024 | 3 | 2028 | MS | 2 | 2.5 | 10 | |||||||||||||||||
56 | 25 | Biogen, BTKi BIIB091 Trial Info | Remyelination Slow-disability EBV-Antiviral | USA | RR | 2 | Recruiting | 4 | 2029 | MS | 2 | 2.5 | 10 | 270 | 2023-07-25 | 2025-07-10 | 2026-11-09 | ||||||||||||||
57 | 26 | Metformin & AMPK - 7 Trials | Remyelination | Many | RR | 2 | Recruiting or Off-label precription | 3 | 2028 | MS LCovid ME/CFS | 2 | 2 | 8 | 36 | 2020-09-22 | 2027-02-22 | 2027-05-31 | ||||||||||||||
58 | 26 | UCSF, NAC (N-Acetyl Cysteine) | Glucose regulation Anti-inflammatory Mitochondria | USA | RR | 2 | Recruiting | 3 | Avilable Now OTC | MS | 2 | 1.5 | 6 | 98 | 2022-02-16 | 2026-02 | 2026-02 | ||||||||||||||
59 | 27 | Alpha Lipoic Acid Info | Neuroprotective Slows brain atrophy | USA | SP | 2 | Completed Published 2017. | 3 | Avilable Now OTC | MS | 2 | 1.5 | 6 | ||||||||||||||||||
60 | 28 | TUDCA Bile acid supplement Info. | Neuroprotective Anti-inflammatory | USA | SP | 1/2 | Completed Published 2024. | 5.5 | Avilable Now OTC | MS | 2 | 1.5 | 6 | 2018-06-19 | 2022-04-28 | 2022-07-05 | |||||||||||||||
61 | 29 | Andrographis | Remyelination | RR | 2 | Completed Published | 3 | Avilable Now OTC | MS | 2 | 2 | 8 | 36 | 2020-09-22 | 2027-02-22 | 2027-05-31 | |||||||||||||||
62 | 31 | GeNeuro, Temelimab | Neuroregenerative Immunomodulator | Many | Treat | 2 | Completed Published | 4 | 2029 | MS ALS LCovid | 2 | 2 | 8 | ||||||||||||||||||
63 | 32 | Harvard, Antivirals for EBV in MS | EBV Antiviral | USA Harvard | RR | Treat | Pilot | Recruiting by Invitation | 4 | 2029 | MS | 2 | 2.5 | 10 | |||||||||||||||||
64 | 33 | Haukeland Univ. Stem Cells Trial | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | Norway | SP | 2 | Recruiting | 4 | 2029 | MS | 2 | 2.5 | 10 | 2021-08-09 | 2024-10-04 | 2025-01-04 | |||||||||||||||
65 | 34 | Umbilical Cord Stem Cells IV & Intrathecal (UMSC01) Trial | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | Taiwan | RR | 1/2 | Recruiting | 4 | 2029 | MS | 2 | 2.5 | 10 | 41 | 09/08/2023 | 12/31/2026 | 2026-12-31 | ||||||||||||||
66 | 35 | Duke Univ, Stem Cells Trial | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | USA | PP | 1 | Recruiting | 5.2 | 2030.2 | MS | 2 | 2.5 | 10 | 20 | 2021-01-24 | 2025-08-30 | 2025-08-30 | ||||||||||||||
67 | 36 | Extracorporeal Photopheresis (ECP) Info1 Info2 Trial. | Neuroregenerative Anti-inflammatory Immunomodulator | UAE | SP | 1/2 | Active, Not Recruiting | 3.5 | 2028.5 | MS | 2 | 2.5 | 10 | 15 | 2022-03-26 | 2025-03 | 2025-06 | ||||||||||||||
68 | 37 | Oculis, OCS-05 Info Trial | Neuroregenerative Anti-inflammatory | France | Optic Neuritis | 2a | Recruiting | 5 | 2030 | MS ON PD Glaucoma Epilepsy | 2 | 2 | Orphan drug designation | 1 | 9 | 2022-12-19 | 2025-08-27 | 2024-09-16 | |||||||||||||
69 | 38 | MBP Tolerizing Vaccine * Trial | MBP-tolerizing | Spain | ALL | Treat | 2 | Recruiting | 5 | 2030 | MS | 2 | 2 | 8 | |||||||||||||||||
70 | 39 | Denali/Sanofi, SAR443820 Info Trial | Many | RR SP | 2 | Recruiting | 5 | 2030 | MS | 2 | 2 | 8 | |||||||||||||||||||
71 | 40 | Contineum, PIPE-307 Muscarinic M1 Antagonist VISTA Trial Info | Remyelination | USA | RR | 2 | Active, Not Recruiting | 3 | 2028 | PMS | 2 | 2 | 8 | 2023-11-06 | 2025-08 | 2025-09 | |||||||||||||||
72 | 41 | Ifenprodil Trial | Remyelination | France | RR | 2 | No Yet Recruiting | 5 | 2030 | MS | 2 | 2 | 8 | 60 | 2024-03-01 | 2027-03-01 | 2027-06-01 | ||||||||||||||
73 | 42 | Low Dose Naltrexone Trial Info on LDN & Prescribers | Anti-inflammatory | Many | ALL | 2 | Recruiting or Off-label precription | 3 | 2028 | MS LCovid ME/CFS | 2 | 1.5 | 6 | ||||||||||||||||||
74 | 43 | MediciNova, Ibudilast MN-166 | Neuroprotective Anti-inflammatory Slow-brain-atrophy | USA | SP PP | 2 | Completed Published. 2018 2024. | 3 | 2028 | MS | 2 | 1.5 | 6 | ||||||||||||||||||
75 | 44 | Hydroxychloroquine HCQ | ↓ Microglial Activity Delays progression | Canada | PP | 2 | Off-label Published 2022 2023. | 4 | 2029 | MS RA | 2 | 1.5 | 6 | ||||||||||||||||||
76 | 45 | Rapamycin | Inhibits mTOR Less plaques, Improve EDSS, T-Cell reg Anti-inflammatory | USA | RR | Treat | Pilot | Completed Published 2018 | MS LCovid ME/CFS | 2018-06-19 | 2022-04-28 | 2022-07-05 | 59 | ||||||||||||||||||
77 | 46 | Spinal Cord Neuromodulator (SCONE™) for Neurogenic Bladder Info Trial | Spinal cord neuromodulation | USA Canada India | ALL | 2 | Recruiting | 3 | 2028 | MS SCI Stroke | 2 | 1.5 | Breakthrough Device | 1 | 7 | ||||||||||||||||
78 | 47 | TAURUS2 Magnetic Stim Myelin Info Trial | Remyelination | Australia | ALL | 2 | Recruiting | 3 | 2028 | MS | 2 | 2 | 8 | 108 | 2024-11-22 | 2024-08-2024 | |||||||||||||||
79 | 48 | Transcranial Magnetic Stimulation There are 10 trials . | ALL | Recruiting | Avilable Now | ||||||||||||||||||||||||||
80 | 49 | Acute Intermittent Hypoxia Trial | Neuroplasticity Motor Function | RR | 2 | Completed Published 2024. | 3 | 2028 | MS | 2 | 1.5 | trial | |||||||||||||||||||
81 | 50 | Kyverna, KYV-101 CAR-T Cell Trial Info | B cell depletor | USA Stanford | SP PP | Treat | 2 | Recruiting | 5 | 2030 | MS Lupus | 2 | 3 | Break- through Therapy | 1 | 13 | |||||||||||||||
82 | 51 | Btristol Myers, CC-97540 CAR-T Cell Info Trial | B cell depletor | Treat | 5 | 2030 | MS | 2 | 3 | 12 | |||||||||||||||||||||
83 | 52 | New Gadolinium-Free MRI Contrast Agent - RVP-001 | A safey trial to test an alternative to gadolinium-based contrast agent | USA CT MA | All | 2 | Recruiting | 2 | |||||||||||||||||||||||
84 | 53 | Iaso, Eque-cel CAR-T Info Trial | B cell depletor | China | SP PP | Treat | 1 | Recruiting | 6 | 2031 | MS | 1 | 3 | 3 | 36 | 2020-09-22 | 2027-02-22 | ||||||||||||||
85 | 54 | Anokion, ANK-700 Inverse Vaccine Trial Results | Immune-tolerance | USA | RR | Treat | 1 | Completed Published. | 5 | 2030 | MS CD T1D | 1.5 | 2.5 | 6 | |||||||||||||||||
86 | 55 | FibroBiologics, CYMS101 Info Trial | Remyelination | USA | RR | 1 | Completed | 5 | 2030 | MS DDD DWC SLE | 1.5 | 2.5 | 6 | ||||||||||||||||||
87 | 56 | FSD Pharma, Lucid-MS Info Trial | Remyelination | Canada | RR | 1 | Completed 03/2024. | 5 | 2030 | MS | 1.5 | 2 | 5 | ||||||||||||||||||
88 | 57 | Synaptogenix, Bryostatin-1 Info Trial | Axonal regeneration Remyelination Synaptogenesis Prevent nerve death Anti-inflammatory | USA Ohio | ALL | 1 | Recruiting | 6 | 2031 | MS AD Autism Fragile-X | 1 | 3 | 3 | 20 | 2024-06-26 | 2026-04-01 | 2026-08-01 | ||||||||||||||
89 | 58 | Allogenic Adipose MSC Stem Cells Intrathecal for PPMS (MAESTRO-4MS) Trial | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | France | 1 | Not Yet Recruiting Start Q4 2024 | 5 | 2030 | MS | 1 | 2.5 | 3 | 10 | 2024-10-01 | 2028-06-01 | 2028-12-01 | |||||||||||||||
90 | 59 | ImStem, Stem Cells Info Trial | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | USA Georgia | RR SP | 1 | Active, Not Recruiting | 5 | 2030 | MS | 1 | 2.5 | 3 | 2021-08-31 | 2027-04-01 | 2027-04-01 | |||||||||||||||
91 | 60 | Neural Stem Cells Brain Injections Info1 Info2 Trial. | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | USA CO Italy | SP | 1 | Completed Published 2023 | 5 | 2030 | MS | 1 | 2.5 | 3 | 15 | 2017-09-09 | 2021-05-29 | 2021-05-29 | ||||||||||||||
92 | 61 | Human Amniotic Mesenchymal Cell Secretome for Neurodegeneration MS & ALS (CONTRASTOME) Trial | Neuroregenerative Anti-inflammatory Immunomodulator MBP-tolerizing | Italy | ALL MS & ALS | Pilot | Planned 4th Qtr 2024 | 7 | 2032 | MS ALS | 1 | 2.5 | 3 | 60 | 2024-09-01 | 2026-03-31 | 2026-09-30 | ||||||||||||||
93 | 62 | Ixazomib SIZOMUS Trial Info | Immunomodulator | UK London | ALL | 1 | Active, Not Recruiting | 5 | 2030 | MS Cancer | 1 | 2 | 2 | 72 | 2020-08-20 | 2020-08-20 | 2023-08-20 | ||||||||||||||
94 | 63 | Indapta, IDP-023 (natural killer cells) + Ocrevus Info | Antiviral | SP PP | Treat | 1 | Planned Q4 2024 | 6 | 2031 | MS Cancer | 1 | 2 | 2 | ||||||||||||||||||
95 | 64 | Lapix, LPX-TI641 Info Trial | Iimmune-tolerance | USA, Jordan | ALL | 1 | Completed Nov 2024 | 5 | 2030 | MS NMOSD MOGAD | 1 | 2 | 2 | 2023-10-30 | 2024-04-15 | 2024-08-01 | |||||||||||||||
96 | 65 | Moderna EBV Vaccine • 1195 Treat • 1189 Prevent Info | Antiviral | USA | ALL | Treat Prevent | 1 | Completed | 5 | 2030 | MS | 1 | 2 | 2 | 2022-04-01 | 2025-12-31 | |||||||||||||||
97 | 66 | NIH, EBV MS Vaccine * Info Trial | Antiviral | USA | SP PP | Prevent | 1 | Recruiting | 6 | 2031 | MS | 1 | 2 | 2 | |||||||||||||||||
98 | ModeX, MDX2201 EBV Vaccine Info Trial | Antiviral | USA | SP PP | Prevent | 1 | Recruiting | 6 | 2031 | MS | 1 | 2 | 2 | ||||||||||||||||||
99 | 67 | USCF, Bazedoxifene Info Trial | Remyelination | USA CA | RR | 1a/2b | Recruiting | 4 | 2029 | MS | 1 | 2 | 2 | ||||||||||||||||||
101 | 69 | Contineum, PIPE-791 LPA1R Antagonist Trial Info | Remyelination | USA | Healthy volunteer | 1 | Recruiting | 6 | 2031 | PMS IPF | 1 | 2 | 2 | ||||||||||||||||||
102 | 70 | Investigating the effect of Cerebral Venous Vasculature on Venous Pressure in Multiple Sclerosis Info | Neurovascular | Asutralia | SP | 1 | Pending funding | 7 | 2030 | MS CD T1D | 1 | 2 | 2 | ||||||||||||||||||
103 | 71 | UTI: Phage Therapy, UTI Vaccines, Antibiotics (Orlynvah) | UTIs are a leading cause of death for PwMS. New antibiotic approved 12/12/2024 | Many | All | Recruiting Completed Approved | Varies | 80 | 2022-08-30 | 2024-05 | 2026-11 | ||||||||||||||||||||
104 | 72 | Pasithea, PAS-002 MS Vaccine - Info | Antiviral | USA | ALL | Treat | 0 | Pending | 8 | 2033 | NF1 ALS MS | 0.5 | 2 | Breakthrough Therapy | 1 | 2 | |||||||||||||||
105 | |||||||||||||||||||||||||||||||
106 | 73 | Simvastatin Trial 2 (MS-STAT2) Info Trial | Neuroprotective Neuroregenerative Anti-inflammatory Slow-brain-atrophy | UK | SP | 3 | Did not meet endpoints 2024 | 1 | MS | 3 | 2 | 18 | 964 | 2018-03-28 | 2024-08-31 | 2024-08-31 | |||||||||||||||
107 | 74 | Biogen, BTKI Orelabrutinib * Trials | Many | RR | Treat | 2 | Partial Hold Dec 2022 then Cancelled | 5 | MS | 2.5 | 2.5 | 16 | 2019-12-19 | 2024-06-01 | |||||||||||||||||
108 | 75 | Famciclovir for EBV in MS * Trial | Antiviral | UK | ALL | Treat | 2 | Completed Report | 4 | MS | 2 | 0 | 0 | ||||||||||||||||||
109 | 76 | Merck, BTKi Evobrutinib Info Trials | Many | RR | Treat | 3 | Did not meet endpoints Dec 2023 | 2 | MS | 3 | 2.5 | 23 | |||||||||||||||||||
110 | 77 | UCSF, Clemastine Info Trial | USA | RR | 2 | 03/2024 Halted Adverse Event | 4 | MS | 2 | 1.5 | 6 | ||||||||||||||||||||
111 | 78 | Atara, ATA188 | USA | SP PP | Treat | 2 | Terminated | 5 | MS | 2.75 | 3 | Breakthrough Therapy | 1 | 24 | |||||||||||||||||
112 | 80 | ||||||||||||||||||||||||||||||
113 | 30 | ||||||||||||||||||||||||||||||
114 | 10 | ||||||||||||||||||||||||||||||
115 | Best viewed on a screen larger than a mobile phone. | 18 | |||||||||||||||||||||||||||||
116 | Scroll down for colmn heading explanations. | ||||||||||||||||||||||||||||||
117 | Tap Trial Name link for a Research Profile page, or use Info and Trial links. | ||||||||||||||||||||||||||||||
118 | Before you discuss a trial with your doctor, contact the trial coordinator to see if you meet inclusion/exclusion criteria. | ||||||||||||||||||||||||||||||
119 | Click All Therapies tab at bottom of screen for all 130+ therapies in the database. | ||||||||||||||||||||||||||||||
121 | Click HERE to join the Solving MS research study group. Members are discussing and joining these trials! | ||||||||||||||||||||||||||||||
122 | |||||||||||||||||||||||||||||||
123 | Column Heading Definitions |